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Abstract
Myelodysplastic syndrome and myeloproliferative neoplasms are clonal myeloid disorders arising from
haematopoietic stem cells that have the tendency to progress into acute myeloid leukaemia. Multiple prognostic
scoring systems have been proposed and utilised in clinical practice to predict disease evolution, however none of
them can predict treatment response. In solid tumours, the relationship between the pro-phagocytic calreticulin and
the anti-phagocytic CD47 is repeatedly investigated. Overexpression of calreticulin has been documented to
produce a pro-phagocytic signal in solid tumour and it is often counteracted by a concomitant expression of the anti-
phagocytic CD47 as they act in response to one another, reflecting an apoptosis vs survival mechanism in response
to chemotherapy. The role of both calreticulin and CD47 are currently poorly understood in myeloid malignancies
including myelodysplastic syndrome and myeloproliferative neoplasms. The aim of this review is to elaborate on the
current understanding round the roles and implications of calreticulin and CD47 signalling with in solid and
haematological cancers, discuss potential roles for calreticulin and CD47 expression in transformation of myeloid
cells in patients with MDS or MPN into AML and how these advances are starting to be used to design new
therapeutic strategies to determine disease progression and treatment response in both solid cancer and myeloid
malignancies.
Keywords: Haematological cancers; Solid cancers; Myelodysplastic
syndrome; Myeloproliferative neoplasms; Acute myeloid leukaemia
Abbreviations: MDS: Myelodysplastic Syndrome; MPN:
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Introduction
Myelodysplastic syndromes (MDS), Myeloproliferative neoplasms
(MPN) and acute myeloid leukaemia (AML) are myeloid malignancies
which are a group of bone marrow diseases arising from clonal
disorders of haematopoietic stem cells. MDS and MPN show
tendencies to develop into AML as these diseases progress [1]. These
diseases originate from a range of genetic events in the hematopoietic
stem cells that lead to dysmyelopoiesis, abnormal differentiation,
increased apoptosis with ineffective haematopoiesis, cytopenias or
leucocytosis [2,3]. Scoring systems for prognosis of this disease are
mainly based on bone marrow/peripheral blood features, cytogenetics
and some clinical manifestations, with no specific genetic marker
highlighting subtypes or stages of these conditions or predicting
transformation and disease progression. In solid tumours,
characterisation of the relationship between the pro-phagocytic
calreticulin (CALR) and the anti-phagocytic CD47 markers is starting
to show they act in response to one another, reflecting a possible
apoptosis vs survival mechanism in response to chemotherapy. It has
been suggested that calreticulin and CD47 could also play a similar
role within myeloid malignancies, however their role within these
diseases has been less well established. In this review using leading
published data (searched for on Pubmed and Google scholar) we will
discuss the current challenges in disease prognosis scoring and
response to treatment within MDS and MPN, describe the current
advances made in characterising the role of CALR and CD47 in solid
tumours and the emerging evidence for a role of CALR and CD47
within MDS and MPN. We will also evaluate how these advances in
our understanding of the role of CALR and CD47 are starting to aid in
acting as diagnostic markers and in therapeutic treatments for these
myeloid malignancies.
Challenges with Characterization and Prognostic
Scoring within Myelodysplastic Syndrome and
Myeloproliferative Neoplasms
Whilst both MDS and MPN are haematopoietic stem cell disorders
that tend to develop on to AML; there are distinct differences between
these disease subtypes. MDS develops from a group of clonal
haematopoietic stem cell disorders, which are characterised by
ineffective haematopoiesis which can develop into cytopenias [4].
Prognostic scoring of MDS is usually characterized on the basis of the
extent of cytopenia, the percentage infiltration of the bone marrow
blasts, and abnormal chromosomal structure upon karyotyping [5].
MPNs are chronic myeloid cancers that are characterized by over
production of mature blood cells, which have the potential to evolve
into AML [6]. The three most common forms of MPN are Essential
thrombocythemia (ET), polycythaemia vera (PV) and myelofibrosis
(MF) [7], which are generally well defined from each other but quite
often with overlapping presentations. Somatic mutations are common
in MPNs; in the majority of patients JAK2 mutations, which affect
JAK/STAT pathway signalling, have been described [8]. Although
other mutations in MPN have been acknowledged, such as the CALR
mutations or cMPL mutations [9], it is thought that all roads lead to
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over activation of the JAK/STAT pathway, with these other mutations
also affecting downstream parts of the JAK/STAT pathway.
Prognosis of MDS and MPN heavily depends on type and severity
of disease. Over the past 25 years classification systems (French-
American-British [FAB] and World Health Organization [WHO])
along with several prognostic-scoring systems, such as the
International Prognostic Scoring System (IPSS), have been widely used
[7,10,11]. Vast heterogeneity in these disorders results in a wide range
of clinical indicators including: signs and symptoms of anaemia,
infection and bleeding complications predominate, with systemic
symptoms or features of autoimmunity being seen in some patients;
perhaps indicative of disease pathogenesis [4].
In MDS, a standard measuring system ranking the risk factors of
each disease into: very low, low, intermediate, high and very high risk
is currently used (IPSS-R) [11] while in MPN a similar prognostic
index (Dynamic International Prognostic Scoring System [DIPSS]) is
only informative in the MF subtype, which is used for estimating
survival from any point in the disease progression [12]. These scoring
systems are mainly based on bone marrow/peripheral blood features,
cytogenetics and some clinical manifestations such as systemic
symptoms or splenomegaly but no specific genetic marker highlights
specific subtypes or stages of those conditions or predicts
transformation and disease progression.
Recent evidence has suggested that certain markers involved in
controlling phagocytosis could be key in both disease progression and
response to treatment within both solid cancer and myeloid
malignancies, with the role of the pro-phagocytic CALR and anti-
phagocytic CD47 recently coming to prominence. Overexpression of
CALR has been documented to produce a pro-phagocytic signal in
solid tumours [13] and it is often counteracted by a concomitant
expression of the anti-phagocytic CD47 [14], reflecting an apoptosis vs
survival mechanism in response to chemotherapy. This expression
pattern could be used as a potential target for therapeutics and
prognostic scoring, as CALR and CD47 has a role in cancer
progression and a potential emerging role in MDS and MPN, which
will be discussed further.
The Roles of Calreticulin and CD47 in Ordaining/
Controlling Phagocytosis
CALR is an endoplasmic reticulum (ER) protein, which has a crystal
structure comprising of an extended proline-rich P-domain inserted
between N- and C-terminal domains. CALR is involved in many
different functions such as calcium homeostasis, protein folding and
post translational modifications [15]. Although CALR is an ER
protein, it is also found throughout the cell and outside the ER is
predominantly located in the membrane and the cytosol [14] where it
is involved in gene expression, cell death, programmed cell removal
and wound healing [16].
The structure of CALR is split into 3 different domains each with a
specific function. The acidic C-domain is responsible for calcium
regulation and binding, predominantly within the ER, and the globular
N-domain and extended P-domain are primarily responsible for the
protein’s chaperone function [14,15]. The C-domain contains the
KDEL amino acid sequence which prevents CALR from being secreted
from the ER. Whilst the KDEL signal resides it to the ER it can
however be translocated to other parts of the cell when needed [17].
KDEL-containing proteins bind to KDEL receptors on the ER affecting
its translocation. If the protein is missing or has a mutated KDEL
region cellular mis-localisation can occur. Localisation studies show
that in myeloid cells CALR is upregulated, however when mutated,
CALR stays located to the ER [17]. 
Expression of CD47 affects cellular proliferation, apoptosis,
adhesion, migration and immune system homeostasis [18]. CD47 is
comprised of an extracellular immunoglobulin (Ig) variable domain, a
five times transmembrane-spanning domain, and a short alternately
spliced cytoplasmic tail [18]. Different CD47 tissue expression patterns
can be seen, which has been proposed to be due to different isoforms
of CD47 determined by alterations in the range of length of the
cytoplasmic tail from between 4-36 amino acid long [19].
The role of CD47 is in vacillating and increasing IgG mediated
phagocytosis when responding to the presence of the arginine-glycine-
aspartate (RGD)-containing extracellular matrix proteins [18]. As a
cell surface glycoprotein of the Ig superfamily, CD47 is a
transmembrane protein that interacts with several molecules including
the protein signal regulatory protein alpha (SIRPα) [19,20]. CD47
blocks phagocytosis mediated by the SIRPα protein. Binding to SIRPα,
CD47 stimulates the SIRPα to initiate a signalling cascade. Signalling
causes recruitment of the src homology-2 domain containing protein
tyrosine phosphatases SHP-1 and SHP-2, resulting in signalling to
inhibit phagocytosis [21], giving CD47 the title of the “don’t eat me
signal” [22].
CALR and CD47 in Cancer Prognosis
CALR expression on the cell surface acts as the pro-phagocytic
signal activating the clearance of aged or damaged cells [23], but also,
as described in different human cancers (ie AML, acute lymphocytic
leukaemia, chronic myeloid leukaemia, ovarian cancer, glioblastoma,
and bladder cancer [13]), has roles in calcium signalling, macrophage-
mediated immune evasion and activation of the unfolded protein
response (UPR), which is responsible for upregulation of molecular
chaperones and degrading misfolded proteins. In solid tumours this is
often counterbalanced by the concomitant expression of the anti-
phagocytic CD47 [14]. Overexpression of CALR mRNA and cell
surface over-exposure of CALR correlates with poor prognosis in
mantle cell lymphoma, superficial and invasive bladder cancer, and
neuroblastoma [13]. Chao et al. [13], showed a correlation between
CALR expression and survival with high expression of CALR
associating with worse survival and high counteracting over expression
of CD47.
In some MPN cases, mutation within exon 9 of CALR has been
found, causing loss of the C-terminal acidic domain, multiple calcium-
binding sites, and the KDEL sequence (24), resulting in a dysfunctional
protein and contributing to over-activation of JAK/STAT pathway
leading to myeloproliferation [17]. However, mutated CALR has also
been shown to cause abnormal localising expressions in the cytosol
and membrane [24,25] and activation of the UPR, which is often
linked to disease progression via arresting protein translation through
the ER compartment [26].
Several studies have shown that targeting CALR translocation to the
cell membrane may represent a new strategy in cancer therapy [27,28].
Translocation from within the cell to the cell membrane is required for
the initiation of the pro-apoptotic signalling of CALR [15]. Treatment
with chemotherapy drugs anthracyclines and the reticulum Ca2+
ATPase Inhibitor thapsigargin, induces CALR translocation to the cell
surface via Endoplasmic Reticulum Resident Protein 57 (ERp57) (a
member of disulfide isomerase family), enhancing the immune
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response and resulting in apoptosis of the cancer cell [27,29]. In
contrast, knocking out ERp57 causes a with decreased surface
expression of CALR and prevents the cells from being attacked by T-
cells resulting in a cell survival benefit [30].
Expression changes in CD47 are a marker of phagocytosis, with
decreased expression in aged or damaged cells leading to homeostatic
phagocytosis. Patients suffering with cancer show high expression rates
of CD47 which correlate with poor clinical outcomes. This is shown in
both solid tumours [21] and also in haematological cancers including
AML [31], when CD47 expression increases on the surface of cancer
cells it signals for survival by evading immune surveillance, acting as a
marker of anti-phagocytosis [32,33].
Emerging Role for CALR and CD47 in Myeloid
Disorders
The CALR/CD47 expression ratio seems to direct the immune
response in MDS/MPN in different ways depending on which signal is
predominant, with high CALR expression signalling for phagocytosis
and high CD47 expression protecting the cancer cells from attack by
the immune system [34]. Macrophage-mediated immunosurveillance
is a form of programmed cell removal (PrCR) by the immune system,
where target cells are recognized and phagocytosed [35], which is
independent of apoptotic removal of cells by the immune system.
Studies have shown CD47 to be the protector of cancer cells from the
PrCR by overpowering the PrCR signals [34]. Blocking SIRPα and
CD47 allows for PrCR of cancer cells and not normal cells to be
targeted due to the higher expression of the eat-me signals, such as
CALR, which are commonly expressed in cancers in cell lines, animal
models and patients [34]. The binding of CALR on the surface of a cell
to LDL receptor related protein 1 (LRP1) receptor on macrophages is a
vital mechanism to induce phagocytosis in targeted cells [13].
Interestingly, upregulation of CALR on the surface of cancer cells is
usually followed by a concomitant upregulation in cell surface
expression of the anti-phagocytic CD47, in a survival response to keep
the cell alive and evade immunosurveillance [34]. Cells being able to
evade immunosurveillance is a key hallmark for cancer [36].
Clearance of the tumour cells can also be triggered by blocking
interaction between SIRPα and CD47, allowing for CALR phagocytosis
signalling on the cell surface to become predominant [37]. MPN
exhibits mutations in CALR (altering its function), seen in 67% of
patients with ET and 88% of those with MF who do not have a JAK2 or
MPL mutation [38]. It has been shown that only mutated CALR cells
resulted in phosphorylation of STAT5 which subsequently activates the
JAK/SAT pathway [39], indicating CALR to be directly involved into
MPN pathogenesis and cells proliferation [40].
Role of CD47 expression in MPN and MDS has not yet been well
defined and characterized, however, membrane over-expression of
CD47 has been measured in AML [31,41] suggesting CD47 as a
potential target in AML therapy. It is known that patients with MDS,
can progress on to AML throughout the course of their treatment. A
gradual increase in CD47 expression has been demonstrated in MDS
cells progressing to AML with lower risk patients expressing the lowest
level comparing with higher levels in high risk MDS. Jiang et al [41]
showed that patients with high risk MDS overexpressed CD47, but
exhibited lower levels of CALR, while in low risk patients it was the
opposite suggesting a potential role for CD47/CALR ratio in disease
progression and prognosis [13]. Interestingly, in post MDS-AML
patients the level of expression of CALR is significantly lower than in
de novo AML (MDS-AML: 10%; de novo AML: 25%) suggesting a
different immune response in secondary AML and potentially a clonal
evolution dictated by immune selection. Loss of CALR is detrimental
to cell phagocytosis, allowing the anti-phagocytic signal CD47 to evade
phagocytosis resulting in a poor prognosis [13]. The role of CALR and
CD47 in MPN is less clear. Post MPN AML cell lines and patients do
not seem to overexpress CD47 as post MDS AML cell lines do
suggesting a possible different mechanism of immunoresistence,
however preliminary data from our laboratory, suggest an upregulation
of CD47 but not CALR in chronic phase MPN (unpublished
observation).
CALR and CD47 Targeting for Anti-cancer and
Myeloid Malignancy Therapy
CALR can be used as a potential target for anti-cancer therapy using
molecules able to enhance CALR expression and stimulate
phagocytosis of the affected cells [15]. In prostate and lung cancer cells,
CALR targeting adenovirus (Ad-CALR/MAGE-A3) have produced an
up regulation of CALR and consequently an increased rate of apoptosis
in the cancer cells [42]. Administration of a chimeric construct of
CALR along with a chemotherapy agent increased treatment response
in mice with mammary tumours [43], indicating the potential for
combined therapy in mammary tumours. In addition, after treatment
with anthracycline, CALR expression on the cell surface correlated
with the overall removal of cancer cells and survival of the patients
[44], resulting in the activation of a tumour-targeting immune
response in AML, neuroblastoma, non-small cell lung
carcinoma,ovarian cancer, and colorectal carcinoma [44].
Anti-CD47 antibodies can block CD47-SIRPα signalling and induce
cancer cells death. Dheilly et al. [45] showed how combining an anti-
CD49 with an anti-CD47 was effective in inducting cell death in
leukemic, lymphoma, pancreatic, and ovarian carcinomas cell lines.
Chemotherapy drugs are considered as the first line treatment for
cancers, however, chemotherapy is not always effective. Combination
therapies have been proposed, using specific chemotherapy drugs in
conjunction with anti-CD47 [46]. Liu et al [47] generated pre-clinical
assessment of a humanised anti-CD47 antibody (Hu5F9-G4) which in
combination with rituximab chemotherapy drug treatment, resulted in
an initial reduction of all blasts in vivo. After day 159 blood counts
(white blood cells, hemoglobin, and platelets), were seen to return to
normal range [48]. Concomitantly, Wang et al, showed that combining
cytarabine in conjunction with anti-CD47 antibody, increases the
antitumor effects in AML comparing with cytarabine alone [48].
Blocking CD47 using CD47 siRNA could also represent a
therapeutic strategy. Wang et al [49] showed efficacy of CD47 siRNAs
in melanoma and lung metastases regression. The CD47 siRNA were
intravenously administered and resulted in reduction of tumour size.
Gholamin et al [50] demonstrated inhibition of CD47 using
humanized anti-CD47 antibody Hu5F9-G4, which increases the
presence of activated macrophages in brain tumours. SIRPα dependent
phagocytosis induced this by blocking the CD47 signal [31].
Macrophages then become active due to the increase in the phagocytic
signals, activating macrophages to phagocytose cancer cells [34].
Further studies are being carried out into both CALR and CD47
targeting which makes the future of the area very interesting.
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Conclusion
The role of CALR and CD47 in myeloid neoplasms is currently
poorly understood. In solid tumours overexpression of CALR produces
a pro-phagocytic signal [13] and it is often counteracted by a
concomitant expression of the anti-phagocytic CD47 [14]. Over
expression of CALR has been seen to correlate with poor prognosis as
it is counteracted by increased CD47 increased expression, which is
critical for cancer cell survival [34]. Several studies demonstrated how
CD47 is often overexpressed in AML [31], allowing the leukaemia cell
to evade immune surveillance and survive [32,33]. During MDS
progression onto AML, the levels of expression of CALR increase but is
immediately counteracted by the concomitant CD47 overexpression,
resulting in a predominate anti-phagocytic message. The expression of
CD47 in MPN is not well defined yet. Preliminarily data from our
laboratory indicate in MPN samples no increase of CALR expression is
seen on the cell surface, whilst CD47 expression is significantly
elevated in ET, PV and MF, indicating a possible different mechanism
of immunoresistance comparing to solid tumour and AML.
Emerging therapeutic strategies targeting CALR and CD47
expression have offered an interesting insight into the roles of CALR
and CD47 in myeloid neoplasms and their implication into
pathogenesis and disease progression. Targeting CALR with the aim of
increasing its expression on the cell surface using an adenovirus (Ad-
CALR/MAGE-A3) [42] resulted in significant increase in cell death
and apoptosis. Blocking the CD47-SIRPAα signalling pathway [31] by
using Hu5F9-G4 has resulted in reduction of CD47 on cancers cells
and consequently increases in cancer cell removal and tumour burden
reduction [47].
CALR and CD47 play vital roles in the pro/anti - phagocytic
mechanisms of cancer cells. Better understanding is required for their
involvement in myeloid malignancies. CALR and CD47 targeted
therapies alone or in combination with standard chemotherapy could
result in better outcome for patients suffering with both
haematological and solid cancers. Further studies are required to better
fully understand the implication of CALR and CD47 expression/
regulation and their prognostic role in disease progression and
treatment response in cancer and the myeloid malignancies.
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